JMP Securities Reiterates Market Outperform on Iovance Biotherapeutics, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $18.
August 17, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics has received a reiterated Market Outperform rating and a maintained price target of $18 from JMP Securities.
The reiterated Market Outperform rating and maintained price target by JMP Securities indicates a positive outlook for Iovance Biotherapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100